AK0406
Beyond's analysis on AK0406
- — ArkBio secures China IND approval for long-acting antiviral AK0406, advancing influenza prophylaxis development
- — ArkBio completes dosing in Australian Phase I trial of long‑acting influenza AFC drug AK0406, moving its antiviral prophylactic program forward